Unknown

Dataset Information

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.


ABSTRACT:

Objective

To determine the potential efficacy of ubrogepant for acute treatment of migraine based on historical experience with triptans.

Background

Although triptans have improved migraine treatment, their efficacy and tolerability may limit their utility in some individuals. Ubrogepant is a small-molecule, oral calcitonin gene-related peptide receptor antagonist approved by the Food and Drug Administration for acute treatment of migraine in adults.

Methods

This post hoc analysis of pooled data from the pivotal trials ACHIEVE I and II, identically designed, randomized, double-blind, phase 3, single-attack trials of ubrogepant in adults with a history of migraine with/without aura, examined the efficacy and tolerability of ubrogepant 50 mg versus placebo based on part

SUBMITTER: Blumenfeld AM 

PROVIDER: S-EPMC8252782 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature